Physician profile
Patrick W Blake
NPI 1871817312
$18,513.85
in general payments reported to CMS, 2019-2025
30 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $322 · 2021: $1,134 · 2022: $1,484 · 2023: $11K · 2024: $2,112 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,478 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,624 · Travel and Lodging: $3,295 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,478.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,623.50 |
| Travel and Lodging | $3,294.77 |
| Education | $261.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $8,004.85 | 2019-2025 | Aklief |
| Merz North America, INC. | $3,834.04 | 2021-2023 | Xeomin |
| Abbvie INC. | $1,655.28 | 2021-2025 | Botox |
| Sun Pharmaceutical Industries INC. | $725.05 | 2019-2025 | Winlevi |
| Janssen Biotech, INC. | $715.89 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $708.24 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $661.70 | 2022-2025 | Sotyktu |
| Amgen INC. | $405.34 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $279.54 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $153.27 | 2019-2023 | Dupixent |
| Regeneron Pharmaceuticals, INC. | $126.19 | 2019 | |
| Lilly USA, LLC | $123.80 | 2020-2023 | Taltz, Olumiant |
| Solta Medical, A Division of Bausch Health US, LLC | $111.56 | 2025 | Clear+Brilliant |
| Vyne Pharmaceuticals INC. | $106.00 | 2020-2021 | |
| Revance Therapeutics, INC. | $105.51 | 2024-2025 | Daxxify |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $105.06 | 2019 | |
| Allergan, INC. | $103.77 | 2020-2022 | |
| Almirall LLC | $101.31 | 2019-2022 | |
| Ucb, INC. | $92.27 | 2019-2024 | Bimzelx |
| Leo Pharma INC. | $81.23 | 2019-2025 | Adbry |
| Organon LLC | $64.68 | 2025 | Vtama |
| Incyte Corporation | $52.27 | 2023-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $48.85 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.97 | 2019-2023 | Siliq, Targretin |
| Genzyme Corporation | $32.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $26.34 | 2025 | |
| Botanix Sb INC | $15.97 | 2025 | Sofdra |
| Mission Pharmacal Company | $13.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Biofrontera INC. | $9.84 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.